Literature DB >> 12018902

K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes.

Dmitry Kislitsin1, Aaron Lerner, Gad Rennert, Zeev Lev.   

Abstract

Colorectal cancer is one of the most common malignancies in the western world, including Israel. An important step in progression includes induction of activating mutations in the protooncogene K-ras. This event is very frequent and is detected in about 40% of colorectal carcinomas. Previous studies of a variety of genetic disorders revealed unique gene mutation prevalence in Jewish populations, attributed both to differences in genetic background and to variability in environmental exposure. To determine the incidence and molecular subtypes of K-ras mutations in colorectal cancer in Israel, compared with other countries, DNA was isolated from a random collection of 105 colorectal carcinoma samples, and K-ras mutations were detected by an improved designed RFLP and direct sequencing. K-ras sporadic mutations in colorectal cancer in Israel are relatively frequent, with a higher fraction in codon 13 than reported thus far. Comparison with other countries shows a vast heterogeneity in terms of the relative abundance of the affected K-ras codon and in type and representation of specific mutations. The heterogeneous distribution found may be due to a variable genetic background and different environmental factors involved in the initiation and propagation of sporadic colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018902     DOI: 10.1023/a:1015090124153

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  Activation of c-K-ras mutations in human gastrointestinal tumors.

Authors:  N Arber; I Shapira; J Ratan; B Stern; H Hibshoosh; M Moshkowitz; M Gammon; I Fabian; Z Halpern
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Occurrence of Ki-ras and p53 mutations in primary colorectal tumors.

Authors:  P Shaw; S Tardy; E Benito; A Obrador; J Costa
Journal:  Oncogene       Date:  1991-11       Impact factor: 9.867

3.  Scrambled exons.

Authors:  J M Nigro; K R Cho; E R Fearon; S E Kern; J M Ruppert; J D Oliner; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

4.  Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa.

Authors:  R G Morris; L J Curtis; P Romanowski; J D Hardcastle; D A Jenkins; M Robinson; A H Wyllie; C C Bird
Journal:  J Pathol       Date:  1996-12       Impact factor: 7.996

5.  Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver.

Authors:  C C Schimanski; U Linnemann; M R Berger
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

6.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.

Authors:  J J Oudejans; R J Slebos; F A Zoetmulder; W J Mooi; S Rodenhuis
Journal:  Int J Cancer       Date:  1991-12-02       Impact factor: 7.396

7.  Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients.

Authors:  J Smith-Ravin; J England; I C Talbot; W Bodmer
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

8.  Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis.

Authors:  M Miyaki; M Seki; M Okamoto; A Yamanaka; Y Maeda; K Tanaka; R Kikuchi; T Iwama; T Ikeuchi; A Tonomura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

9.  Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma.

Authors:  M Tobi; F C Luo; Z Ronai
Journal:  J Natl Cancer Inst       Date:  1994-07-06       Impact factor: 13.506

10.  Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma.

Authors:  G C Burmer; P S Rabinovitch; L A Loeb
Journal:  Environ Health Perspect       Date:  1991-06       Impact factor: 9.031

View more
  12 in total

1.  Detection of K-ras gene mutation in fecal samples from elderly large intestinal cancer patients and its diagnostic significance.

Authors:  Jun Wan; Zi-Qi Zhang; Wei-Di You; Hua-Kui Sun; Jian-Ping Zhang; Ya-Hong Wang; Yong-He Fu
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

2.  The Jerusalem Perinatal Study cohort, 1964-2005: methods and a review of the main results.

Authors:  Susan Harlap; A Michael Davies; Lisa Deutsch; Ronit Calderon-Margalit; Orly Manor; Ora Paltiel; Efrat Tiram; Rivka Yanetz; Mary C Perrin; Mary B Terry; Dolores Malaspina; Yechiel Friedlander
Journal:  Paediatr Perinat Epidemiol       Date:  2007-05       Impact factor: 3.980

3.  Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation.

Authors:  Jing Gao; Yan-Yan Li; Ping-Nai Sun; Lin Shen
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

4.  Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

Authors:  Hong Shen; Ying Yuan; Han-Guang Hu; Xian Zhong; Xiao-Xian Ye; Mo-Dan Li; Wei-Jia Fang; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

5.  Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.

Authors:  Zuo Yunxia; Cao Jun; Zhu Guanshan; Lu Yachao; Zhou Xueke; Li Jin
Journal:  BMC Med Genet       Date:  2010-02-26       Impact factor: 2.103

6.  Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression.

Authors:  Shakir M Saud; Weidong Li; Nicole L Morris; Matthias S Matter; Nancy H Colburn; Young S Kim; Matthew R Young
Journal:  Carcinogenesis       Date:  2014-10-03       Impact factor: 4.944

7.  Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.

Authors:  Grigoriy A Yanus; Anna V Belyaeva; Alexandr O Ivantsov; Ekatherina Sh Kuligina; Evgeny N Suspitsin; Natalia V Mitiushkina; Svetlana N Aleksakhina; Aglaya G Iyevleva; Olga A Zaitseva; Olga S Yatsuk; Tatiana V Gorodnova; Tatiana N Strelkova; Sofia A Efremova; Alla Yu Lepenchuk; Altn N Ochir-Garyaev; Moisey B Paneyah; Dmitriy E Matsko; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-08-14       Impact factor: 3.064

8.  Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.

Authors:  Samuel Murray; Vasilios Karavasilis; Mattheos Bobos; Evangelia Razis; Savvas Papadopoulos; Christos Christodoulou; Paris Kosmidis; George Fountzilas
Journal:  J Exp Clin Cancer Res       Date:  2012-09-19

9.  Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.

Authors:  Samuel Murray; Mattheos Bobos; Nikolaos Angouridakis; Angelos Nikolaou; Helena Linardou; Evangelia Razis; George Fountzilas
Journal:  J Oncol       Date:  2011-01-03       Impact factor: 4.375

Review 10.  Colorectal Cancer Biomarkers: Where Are We Now?

Authors:  Maria Gonzalez-Pons; Marcia Cruz-Correa
Journal:  Biomed Res Int       Date:  2015-05-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.